Key result
First-dose administration of perindopril resulted in significantly fewer hypotensive episodes compared to captopril (15% vs. 42%, p < 0.0001) in patients with congestive heart failure.
Why the study?
Does perindopril compared to captopril reduce the incidence of first-dose hypotension in patients with congestive heart failure?
RCT (n=240)
Open-label
randomized
Yes
Does perindopril compared to captopril reduce the incidence of first-dose hypotension in patients with congestive heart failure?
Initiation of heart failure treatment with the long-acting ACE inhibitor perindopril results in significantly less first-dose hypotension and better haemodynamic tolerance compared to the short-acting ACE inhibitor captopril.
Answers are grounded in this paper and cite their sources.
Supports preferring perindopril over captopril for ACEI initiation in HF; confirms better first-dose tolerance with long-acting agents.
SummaryBackground: Angiotensin Converting Enzyme inhibitors (ACEi's) confer significant mortality and morbidity benefits in all functional grades of chronic heart failure (CHF). However, physicians' concerns regarding the possible occurrence of first-dose hypotension appear to be a contributing factor to their under-utilisation in both hospital and primary care settings. We investigated whether long-acting and short-acting ACEi's differ in their haemodynamic responses to the first-dose in patients with CHF.Method: This was a multicentre, randomised, open, two-parallel-group study of captopril 6.25 mg and perindopril 2mg. 240 patients with CHF, age 68.9 ± 8.9 years, of whom 66% were male, NYHAII—IV, with average blood pressure baseline values of 132.2 ± 16.2/78.5 ± 10.5mmHg for systolic and diastolic blood pressure, and left ventricular ejection fraction (LVEF) of 31.3 ± 7.4% received either captopril (n = 124) or perindopril (n = 116). Blood pressure was continuously monitored during the 8 h following drug intake. Minimum levels and maximum decreases in systolic, diastolic and mean arterial pressures were measured, along with the incidence of hypotensive episodes defined as mean blood pressure (MBP) fall > 20mmHg, whether symptomatic or not. Subgroups of patients distributed according to age, baseline blood pressure (BP) and LVEF were subsequently analysed.Results: Overall, a statistically significant treatment effect in favour of perindopril was observed. First-dose hypotension was observed more frequently following captopril than perindopril administration, with lower MAP minimal levels (78.0 ± 8.9 vs. 84.5 ± 10.1 mmHg, p < 0.0001), greater maximum falls (17.6 ± 8.3 vs. 12.8 ± 7.3mmHg, p < 0.0001) and more frequent hypotensive episodes (42% vs. 15%, p < 0.0001). The incidence of at least one symptomatic episode was also significantly higher with captopril (10 patients vs. one patient, p = 0.029). Subgroup analyses according to age (< 70 years or > 70 years) or LVEF (< 30% or > 30%) reflected the main result.Conclusion: Initiation of treatment with ACE inhibitors is associated with different haemodynamic and clinical tolerances in CHF patients, regardless of their risk for hypotension, with possible clinical implications.
No takes yet. Share an insight, caveat, or question.
Anthopoulos et al. (2001) conducted an RCT in Congestive heart failure (n=240). Perindopril vs. Captopril 6.25 mg was evaluated on Incidence of hypotensive episodes (mean blood pressure fall > 20 mmHg) (p=< 0.0001). First-dose administration of perindopril resulted in significantly fewer hypotensive episodes compared to captopril (15% vs. 42%, p < 0.0001) in patients with congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: